An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACCESS-EXT; ACCESS-EXTENSION
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 25 Jun 2025 Planned primary completion date changed from 5 Feb 2029 to 26 Feb 2029.
- 02 Jun 2025 Planned End Date changed from 5 Feb 2029 to 26 Feb 2029.
- 07 Dec 2024 According to Regeneron Pharmaceuticals media release , company announced positive updated result from this trial at the American Society of Hematology (ASH) 2024 Annual Meeting